Fiche société
Hangzhou Sumgen Biotech Co., Ltd.
Traitements, essais et publications liés.
Traitements2programmes
Essais1liés
Publications0liées
SourceDBlocale
Traitements
2| Molécule | Indication / population | Phase | Objectif | Pays | Résultat |
|---|---|---|---|---|---|
| SG301 SC InjectionThis is a randomized, double-blind, placebo-controlled phase I clinical study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of single dose in healthy volunteers and multiple doses of SG301 SC injection in participants with systemic lupus erythematosus (SLE). | Lupus | Phase 1 | À vérifier | China | À vérifier |
| SG301 SC InjectionThis is a randomized, double-blind, placebo-controlled phase I clinical study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of single dose in healthy volunteers and multiple doses of SG301 SC injection in participants with systemic lupus erythematosus (SLE). | Lupus | Phase 1 | À vérifier | China | À vérifier |
Essais cliniques
1| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| SG301 SC Injection | Lupus | Phase 1 | NCT06144710 | SG301-SC Injection Safety Study in Subjects With Systemic Lupus Erythematosus | COMPLETED |
Publications
0| Molécule | Indication / population | Titre | Journal | Date |
|---|---|---|---|---|
| Aucune publication. | ||||